Is Neuronetics Stock a Good Investment?
Neuronetics Investment Advice | STIM |
- Examine Neuronetics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Neuronetics' leadership team and their track record. Good management can help Neuronetics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Neuronetics' business and its evolving consumer preferences.
- Compare Neuronetics' performance and market position to its competitors. Analyze how Neuronetics is positioned in terms of product offerings, innovation, and market share.
- Check if Neuronetics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Neuronetics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Neuronetics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Neuronetics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Neuronetics Stock
Researching Neuronetics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 64.0% of the company shares are owned by institutional investors. The book value of Neuronetics was at this time reported as 0.92. The company recorded a loss per share of 0.94. Neuronetics had not issued any dividends in recent years.
To determine if Neuronetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuronetics' research are outlined below:
| Neuronetics generated a negative expected return over the last 90 days | |
| Neuronetics has high historical volatility and very poor performance | |
| Neuronetics may become a speculative penny stock | |
| Neuronetics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 71.35 M. Net Loss for the year was (30.19 M) with profit before overhead, payroll, taxes, and interest of 49.72 M. | |
| Neuronetics currently holds about 73.7 M in cash with (32.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Neuronetics has a poor financial position based on the latest SEC disclosures | |
| Roughly 64.0% of the company shares are owned by institutional investors | |
| Latest headline from investing.com: Neuronetics director Robert Cascella buys 102,550 in company stock |
Neuronetics Quarterly Long Term Debt |
|
Neuronetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuronetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuronetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Neuronetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Neuronetics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2021-08-03 | 2021-06-30 | -0.24 | -0.29 | -0.05 | 20 | ||
2021-03-02 | 2020-12-31 | -0.24 | -0.19 | 0.05 | 20 | ||
2019-11-05 | 2019-09-30 | -0.43 | -0.37 | 0.06 | 13 | ||
2024-03-05 | 2023-12-31 | -0.26 | -0.19 | 0.07 | 26 | ||
2023-03-07 | 2022-12-31 | -0.38 | -0.3 | 0.08 | 21 | ||
2020-11-02 | 2020-09-30 | -0.28 | -0.18 | 0.1 | 35 | ||
2020-08-04 | 2020-06-30 | -0.51 | -0.41 | 0.1 | 19 |
Neuronetics Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Neuronetics target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Neuronetics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 4 | Strong Buy |
Most Neuronetics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Neuronetics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Neuronetics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationNeuronetics Target Price Projection
Neuronetics' current and average target prices are 1.91 and 8.00, respectively. The current price of Neuronetics is the price at which Neuronetics is currently trading. On the other hand, Neuronetics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Neuronetics Target Price
Neuronetics Analyst Ratings
Neuronetics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Neuronetics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Neuronetics' financials, market performance, and future outlook by experienced professionals. Neuronetics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Neuronetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuronetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuronetics backward and forwards among themselves. Neuronetics' institutional investor refers to the entity that pools money to purchase Neuronetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-03-31 | 380.5 K | Dafna Capital Management Llc | 2024-03-31 | 313.7 K | Geode Capital Management, Llc | 2024-03-31 | 286.6 K | Acadian Asset Management Llc | 2024-03-31 | 264.3 K | Marshall Wace Asset Management Ltd | 2024-03-31 | 217.6 K | Boothbay Fund Management, Llc | 2024-03-31 | 162.1 K | Hightower Advisors, Llc | 2024-03-31 | 158.2 K | Dimensional Fund Advisors, Inc. | 2024-03-31 | 147 K | Renaissance Technologies Corp | 2024-03-31 | 143.5 K | Archon Capital Management Llc | 2024-03-31 | 2.5 M | Cannell Capital Llc | 2024-03-31 | 2.5 M |
Neuronetics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 60.6 M.Market Cap |
|
Neuronetics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.26) | (0.27) | |
| Return On Equity | (0.88) | (0.93) |
Determining Neuronetics' profitability involves analyzing its financial statements and using various financial metrics to determine if Neuronetics is a good buy. For example, gross profit margin measures Neuronetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuronetics' profitability and make more informed investment decisions.
The data published in Neuronetics' official financial statements typically reflect Neuronetics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Neuronetics' quantitative information. For example, before you start analyzing numbers published by Neuronetics accountants, it’s essential to understand Neuronetics' liquidity, profitability, and earnings quality within the context of the Health Care Equipment & Supplies space in which it operates.
Evaluate Neuronetics' management efficiency
Neuronetics has return on total asset (ROA) of (0.1537) % which means that it has lost $0.1537 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7248) %, meaning that it created substantial loss on money invested by shareholders. Neuronetics' management efficiency ratios could be used to measure how well Neuronetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 18th of June 2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Neuronetics' Net Tangible Assets are very stable compared to the past year. As of the 18th of June 2024, Other Current Assets is likely to grow to about 7.6 M, while Non Current Assets Total are likely to drop about 13.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.19 | 1.25 | |
| Tangible Book Value Per Share | 1.05 | 1.10 | |
| Enterprise Value Over EBITDA | (3.01) | (3.16) | |
| Price Book Value Ratio | 2.43 | 1.94 | |
| Enterprise Value Multiple | (3.01) | (3.16) | |
| Price Fair Value | 2.43 | 1.94 | |
| Enterprise Value | 828.8 K | 787.4 K |
The analysis of Neuronetics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Neuronetics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Neuronetics Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 2.315 |
Basic technical analysis of Neuronetics Stock
As of the 18th of June 2024, Neuronetics secures the Risk Adjusted Performance of (0.04), standard deviation of 6.74, and Mean Deviation of 4.15. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Neuronetics, as well as the relationship between them. Please verify Neuronetics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Neuronetics is priced some-what accurately, providing market reflects its recent price of 1.91 per share. Please also check out Neuronetics jensen alpha, which is currently at (0.50) to check the company can sustain itself at a future point.Neuronetics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuronetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuronetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuronetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Neuronetics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Neuronetics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.39) | |||
| Mean Deviation | 4.15 | |||
| Coefficient Of Variation | (1,470) | |||
| Standard Deviation | 6.74 | |||
| Variance | 45.39 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.40) | |||
| Maximum Drawdown | 56.6 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 9.49 | |||
| Skewness | (0.54) | |||
| Kurtosis | 8.87 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.39) | |||
| Mean Deviation | 4.15 | |||
| Coefficient Of Variation | (1,470) | |||
| Standard Deviation | 6.74 | |||
| Variance | 45.39 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.76) | |||
| Treynor Ratio | (0.40) | |||
| Maximum Drawdown | 56.6 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 9.49 | |||
| Skewness | (0.54) | |||
| Kurtosis | 8.87 |
Consider Neuronetics' intraday indicators
Neuronetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Neuronetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Neuronetics Corporate Filings
8K | 6th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 5th of June 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 30th of May 2024 Other Reports | ViewVerify | |
| 11th of April 2024 Other Reports | ViewVerify |
Neuronetics Stock media impact
Far too much social signal, news, headlines, and media speculation about Neuronetics that are available to investors today. That information is available publicly through Neuronetics media outlets and privately through word of mouth or via Neuronetics internal channels. However, regardless of the origin, that massive amount of Neuronetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Neuronetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Neuronetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Neuronetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Neuronetics alpha.
Neuronetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Neuronetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Neuronetics Corporate Management
| Rusty Page | Senior Quality | Profile | |
| Lisa MetznerRosas | Senior Officer | Profile | |
| Andrew Macan | Gen VP | Profile | |
| Claire Sears | VP Marketing | Profile | |
| Rick Grubbs | Senior Accounts | Profile | |
| Cory Anderson | Senior Clinical | Profile | |
| Kara Thornton | VP Director | Profile |
Additional Information and Resources on Investing in Neuronetics Stock
When determining whether Neuronetics is a strong investment it is important to analyze Neuronetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neuronetics' future performance. For an informed investment choice regarding Neuronetics Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 2.523 | Quarterly Revenue Growth 0.121 | Return On Assets (0.15) | Return On Equity (0.72) |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Neuronetics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.